Company ProfilePremium

AfroCentric Investment Corporation Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
AfroCentric Investment Corporation Limited - Company showcase

Year Founded & Workforce

1988

5,899 Employees

AfroCentric Investment Corporation Limited logo

AfroCentric Investment Corporation Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AfroCentric Investment Corporation Limited Overview

AfroCentric is a JSE-listed, Sanlam-controlled healthcare investment holding company. Its core asset is Medscheme, one of South Africa's longest-established medical scheme administrators and managed care providers (55 years old on 1 March 2026). Around Medscheme sit specialist risk businesses:

  • Aid for AIDS (HIV disease management)

  • DENIS (dental capitation)

  • Scriptpharm (pharmacy benefit and oncology risk management)

  • Pharmacy Direct, a courier pharmacy that delivers about 1.4 million public-sector chronic scripts per month under the Department of Health's CCMDD programme

The Group managed about 4.09 million lives in FY2025. That base fell to about 3.3 million after Bonitas Medical Fund, its largest client for 43–44 years, moved administration to Momentum Health and managed care to Private Health Administrators (PHA) on 1 June 2026.

The investment case has shifted from a growth-oriented healthcare ecosystem within Sanlam to a turnaround. The turnaround rests on four levers:

  • a cost reset after a R1.37bn impairment year

  • disposal of non-core pharmaceutical manufacturing (Activo, completed August 2026)

  • defence of the remaining scheme book

  • a pivot toward capitation and value-based care


Company's own description (FY2025 Directors' Report and H1 2026 results). AfroCentric describes itself as a JSE-listed investment holding company. It operates in, and provides specialised services to, the public and private healthcare sectors, with the aim of making quality healthcare more accessible and affordable to members and beneficiaries [S1]. Its stated principal objective is to deliver efficient health management services and quality products at manageable and affordable cost. In its 2026 interim materials, the Group describes its offering as integrated health management solutions: medical scheme administration, managed care, medicine provision, wellness services and digital health innovations, across public and private sectors [S5].

Independent characterisation. AfroCentric is in substance a B2B healthcare services outsourcer with three economic engines.

  1. Fee-based scheme administration and managed care (the core).

    • Medscheme earns contracted per-member-per-month (PMPM) administration and managed care fees from medical schemes. These are non-profit, member-owned funds regulated by the Council for Medical Schemes (CMS).

    • Revenue is annuity-like but tied to tender cycles, typically 3–5-year contracts, and to scheme membership.

    • The model is labour- and IT-intensive. Employee benefit costs were R2,795m, or 38% of FY2025 continuing revenue [S1].

  2. Risk-bearing capitation businesses.

    • DENIS (dental), Scriptpharm (chronic, HIV and oncology medicine) and the new spinal-care risk transfer model take on utilisation risk for a fixed capitation fee.

    • Capitation fund revenue was R834m in H1 2026, against capitation expenses of R825m [S4]. Margins depend on actuarial pricing and claims control.

    • Management cites these lines as its highest-quality earnings. DENIS operational earnings grew 26.2% and Scriptpharm oncology profitability grew 29% in FY2025 [S6].

  3. Pharmaceutical distribution (retail cluster).

    • Pharmacy Direct, a courier pharmacy serving private scheme members and the public sector via CCMDD, plus Curasana (wholesale).

    • This is a high-volume, thin-margin, working-capital-intensive business. Courier trading margin fell from 6.8% in 2024 to 2.2% in 2025 [S6].

    • Activo (generic manufacturing and marketing) was sold to Portugal's FHC Group effective 31 August 2026 [S4].

Revenue model mix (H1 2026, continuing operations; total R3,485.4m) [S4]:

About 88% of revenue is service or contract revenue recognised over time. About 12% is product revenue recognised at a point in time [S4].

Value chain position. AfroCentric sits between funders (medical schemes, government programmes, employers) and providers (hospitals, doctors, pharmacies). It performs:

  • claims adjudication (about 10.2 million provider claim lines per month, more than 99% auto-adjudicated) [S7]

  • pre-authorisation and case management

  • disease management

  • provider network contracting

  • fraud, waste and abuse detection

  • medicine dispensing and logistics

Customer types.

  • Open medical schemes, such as Fedhealth and Medshield. Bonitas was a client until 31 May 2026.

  • Restricted (employer) schemes, including GEMS (a managed care client), POLMED (administered since 2016) and Sisonke (from 1 May 2026) [S18][S22][S34].

  • The national and provincial Departments of Health (CCMDD).

  • Corporate employers (onsite clinics, wellness, EAP, gap and primary care cover).

  • Individual members (gap cover via a Sanlam/Centriq cell).

Medscheme had 14 medical scheme clients as at January 2026, including GEMS [S18].

End-markets.

  • South African private medical scheme administration and managed care.

  • Public-sector chronic medicine distribution.

  • Employee health and wellness.

  • Selected Southern African markets: Namibia, Mauritius, Botswana (via an associate) and Eswatini. FY2025 Africa revenue was R261m [S6].

Strategy

Stated strategy (FY2025 Integrated Report, "Vision 2030"). The strategy rests on four objectives [S7][S8]:

  1. Building a winning health offering in partnership with Sanlam.

  2. Driving clinical innovation, through value-based care and capitation risk transfer.

  3. Investing in data, digital and technology.

  4. Evolving culture and the operating model.

The stated purpose is "enhancing the quality of life of our stakeholders". The vision is "transforming healthcare". The mission is to innovate an integrated, sustainable healthcare model that measurably improves access [S8].

Sanlam collaboration goals (FY2025 Directors' Report) [S1]:

  • A health-to-wealth-to-protection client proposition.

  • A holistic corporate wellness model with Sanlam Corporate Services.

  • Growth and retention of scheme membership.

  • Growth and retention of the gap and primary health insurance books.

Post-Bonitas turnaround programme (H1 2026) [S4]:

The Board's original four response priorities were [S17]:

  1. Restructure to the new revenue reality.

  2. Protect the core (3.3m beneficiaries).

  3. Reorganise the operating model.

  4. Simplify the portfolio.

The H1 2026 results expanded these into six execution priorities:

  1. Protect service delivery and client confidence.

  2. Complete the Bonitas wind-down responsibly.

  3. Realign the cost base to future scale.

  4. Redesign organisational structures and support functions.

  5. Simplify the portfolio.

  6. Sequence strategic investment by affordability and measurable value.

The 2026 interim commentary states that the immediate priority is "no longer growth at legacy scale" but stabilisation, cash preservation and restoring sustainable earnings [S4].

Initiatives in the last 24 months

InitiativeDateStatus / targetSource
Strategy refresh and operating model reviewFY2024–FY2025Completed. Capability-based delivery model in place.[S11b], [S7]
Orthocare Spinal Risk Transfer pilot (Fedhealth, Medshield)1 Jan 2025Break-even in the pilot phase; to be scaled[S6]
Integrated PBM (Medscheme + Scriptpharm)2,025Ongoing integration[S7]
Pharma cluster cost rationalisationApr 2025Pharmacy Direct and Curasana operating profit up from R1.3m to R35.7m (H1 2025 vs H1 2026)[S6], [S4]
Data centre relocation; new AfroCentric Technologies platformApr 2025Completed[S7]
Core claims and pre-authorisation replacement (decision engine); RPA/AI2024–202689% end-to-end automation on targeted workflows[S7]
Contact centre modernisation (AI engagement platform)2025–2026Implementation under way[S7]
ADS / Wellworx sale to Sanlam; distribution via Sanlam Health DistributionJul 2025Completed[S6]
Health Rewards by Sanlam (Fedhealth app)2025/26Live. Enhanced loyalty milestone planned for 2027.[S4]
Credit Gateway (employee financial wellbeing)2,025Launched[S7]
Activo disposalDec 2025 – Aug 2026Completed 31 Aug 2026[S4]
Section 189A restructuring (Bonitas-servicing staff)H1 2026Executed; termination costs taken in H1 2026[S4]
Broker portal relaunch2,026Scheduled[S7]
Capital preservation (no FY2025 dividend)Mar 2026Board policy for the short to medium term[S6]

ESG commitments. Level 1 B-BBEE maintained. Specific emissions or sustainability targets were not located in the sources reviewed.

Cost programme targets. Quantified savings targets are not publicly disclosed.

Medium-term financial targets and guidance. Not publicly disclosed. Management has guided only qualitatively: it expects the operating environment to remain challenging, with the full financial impact of the contract loss continuing to show in future reporting periods [S4].

Products & Services

Detailed specifications and pricing are not published for most products. Where pricing is not disclosed, the pricing model is inferred from the revenue line under which the product is reported [S4].

Medical scheme administration, risk management and technology cluster

OfferingDescriptionTarget customerLaunch / statusPricing model
Medscheme – scheme administrationMembership, contributions, claims processing, provider payment, call centres and regulatory reporting for medical schemes. About 10.2m provider claim lines per month, more than 99% automated. 76% automation on about 150,000 hospital claims per month.Open and restricted medical schemes (14 scheme clients as at Jan 2026, including GEMS; POLMED; Fedhealth; Medshield; Sisonke from May 2026)Operating since 1971PMPM administration fees, under 3–5-year tender contracts
Medscheme – managed care / health risk managementHospital pre-authorisation, case management, chronic and disease management, PMB management, mental health admissions, clinical protocolsMedical schemesOngoingPMPM managed care fees
Aid for AIDS (AfA)HIV/AIDS disease management programmeMedical schemes (managed care)Long-standingManaged care fees
Orthocare Spinal Risk Transfer ModelMultidisciplinary biopsychosocial pathway for chronic lower back pain, aimed at reducing unnecessary spinal surgery. Pilots in Fedhealth and Medshield reached break-even.Medical schemesLaunched 1 Jan 2025Risk transfer / capitation
Oncology Performance-Based Reimbursement ModelOutcome-linked oncology treatment pathwaysMedical schemesOngoingPerformance-based reimbursement
Fraud, waste, abuse and error programmes (historically "Medscheme Forensic Services" and "Insurance Fraud Manager")Claims oversight and provider billing analyticsSchemes and insurersOngoingFees / shared savings (not disclosed)
DENIS (Dental Information Systems)Dental benefit management and dental capitation. FY2025 operational earnings +26.2%.Medical schemesAcquired FY2021Capitation
KlinikkaHealth administration / managed care subsidiary listed among group companies. Detailed product scope not publicly disclosed.———
AfroCentric TechnologiesCore administration platforms ("Nexus and other healthcare administration systems", carrying value R897.5m at Jun 2026), a real-time rules-based decision engine, Enterprise Data Exchange, and RPA/AI (87 processes, 130 bots, about 240,000 work items per month)Internal (Medscheme) and external IT revenueOngoing modernisation. New platform adopted 2025. Data centres relocated April 2025.Intercompany IT fees; segment revenue R675.5m in FY2025
Provider portalClaims review, benefit verification and remittances. 35,775+ practices and 245 bureaus.Healthcare providersLaunched Jul 2024Bundled
QR point-of-care toolDeployed at 516 practice locations (3,251 scans)Members and providers2,025Bundled
Broker portal (redesigned)Reporting, product mapping and onboarding. Real-time quotes planned.IntermediariesLaunch scheduled 2026Bundled
Health Rewards by SanlamDigital health engagement and rewards in the Fedhealth member app. Enhanced loyalty milestone planned for 2027.Fedhealth membersLaunched 2025/26—
Medscheme Namibia / Namibia Health Risk Solutions / Medscheme MauritiusAdministration and managed care outside South Africa. Namibia membership grew about 2% in 2025.Schemes in Namibia, Mauritius and othersOngoingAdministration fees (R110m in H1 2026)
Associated Fund Administrators (Botswana)Associate company, scheme administration in BotswanaBotswana schemesAssociateEquity-accounted

Sources: [S4][S6][S7][S17][S18][S22].

Pharmaceutical cluster

OfferingDescriptionTarget customerStatusPricing model
Pharmacy Direct – Public (CCMDD)Courier dispensing and distribution of chronic medication for the Department of Health's Central Chronic Medicines Dispensing and Distribution programme. 1.417m scripts per month in FY2025 (up 6.6%), serving 2.4m+ patients. Integrated with the SyNCH platform.National and provincial Departments of HealthRecord volumes in FY2025Per-script fee (declining price per script)
Pharmacy Direct – PrivateCourier pharmacy for scheme members, integrated with Medscheme and AfA for real-time chronic authorisations. 105,560 scripts per month in FY2025, down from 157,759.Medical scheme members (DSP arrangements)Lost Bonitas DSP status (Feb 2025)Script dispensing fee plus product margin
Curasana WholesalersPharmaceutical wholesalePharmaciesOngoingWholesale margin
Scriptpharm Risk ManagementPharmacy benefit management, formulary and compliance management (more than 90% generic substitution), chronic, HIV and oncology capitation. Delivered savings of R69m (chronic) and R240m (HIV) for two schemes, and R65m (oncology) for a large scheme.Medical schemesLost Bonitas medicine management contract from 1 Jun 2026Capitation and risk-sharing
Activo Health / Forrester Pharma / Activo Healthcare Assets (discontinued)Generic medicines (OTC, antiretrovirals, acute and chronic), vitamins and nutraceuticalsRetail pharmacy, the state, GEMS (historically)Sold to FHC Group, 31 Aug 2026Product sales

Sources: [S4][S6][S7][S26].

Corporate solutions cluster

OfferingDescriptionTarget customerStatusPricing model
AfroCentric Workcare / Employee Health SolutionsNurse-led onsite clinics and mobile nurse services. Online booking and InBody scanners planned.EmployersOngoingService fees
AfroCentric Wellness / The Cheese Has MovedDigital wellness, mental health support, gamified engagement, WhatsApp channels, anonymised employer analyticsEmployersOngoingFees
Credit GatewayEmployee debt management and financial wellbeingEmployers / employeesLaunched 2025—
Sanlam Gap Cover (cell captive via Centriq Insurance)Gap cover, with automated gap claims integrated with Medscheme-administered schemes. Carrying value R87.7m at Jun 2026.Individuals and employer groupsOngoingInsurance premiums (insurance revenue R74.3m in H1 2026)
Medgap Cover (Guardrisk cell)Gap coverIndividualsCeased underwriting 1 Jul 2025; cell closed 30 Jun 2026—
AfroCentric Health Insure / Essential Medical (EssentialMED) / AfroCentric Integrated Health Administrators / AfroCentric Integrated SolutionsPrimary health insurance, gap products and integrated administrationLow-to-middle income market, employersOngoingPremiums / fees
Fedhealth Elect and Savvy + Sanlam Primary Care bundlesLow-cost scheme options combined with unlimited primary care outside hospitalEmployersOngoingPackaged
Warona Health Emergency Medical Services, Allegra, Memo DigitalListed group entities. Product details not publicly disclosed.———

Sources: [S1][S4][S7].

Divested distribution offerings. AfroCentric Distribution Services, Tendahealth, AfroCentric Financial Services and Wellworx were sold to Sanlam Life in July 2025. The distribution function now operates as Sanlam Health Distribution within Sanlam Corporate Distribution [S6][S7].

Financial Narrative

Income statement, five years

Reported basis; R m unless stated. FY2021–FY2024 are years to 30 June. FY2025 is the year to 31 December, on a continuing-operations basis excluding Activo.

Sources and notes:

  • FY2021/FY2022: SENS 13 Sep 2022 [S13]. FY2023 (restated) and FY2024: SENS 3 Sep 2024 [S12]. FY2025: AFS and SENS 4 Mar 2026 [S1][S2].

  • Diluted EPS for FY2021–FY2024 is not separately reported in the short-form announcements; basic EPS is shown as a proxy.

  • Dividends per share follow the payment history: interim plus final for FY2021 and FY2022; an 11c interim for FY2024; nil for FY2025 [S31][S14][S1].

  • FY2023 headline earnings per press reporting was R217.3m restated, against an originally reported HEPS of 36.2c [S16].

Transition period, 6M to 31 Dec 2024 (not included above):

  • Revenue R3,765.4m (re-presented for continuing operations; originally R4,240.9m).

  • Profit before tax R225.1m.

  • Basic loss R125.9m.

  • Headline earnings R31.9m.

  • HEPS 3.80c, EPS (14.96)c, dividend 6c.

Sources: [S1][S2][S11].

Gross profit. Not reported. The statement of profit or loss is presented by nature, not function. FY2025 product cost of sales (cost of pharmaceutical products R804.2m plus distribution R57.3m) against retail segment revenue gives a retail gross margin of about 36% on a segment basis. This is an analyst computation from [S1][S4].

Margins

These are analyst calculations.

FY2025 non-IFRS operating profit was R678.8m, a 9.1% margin on segment revenue of R7,446.8m [S4]. The company cites "R679 million in operational earnings" [S6].

Earlier operating profit. Full-year non-IFRS operating profit for FY2021–FY2024 was not located in the sources reviewed. FY2020 operating profit was R960.7m on revenue of R6,441m (14.9%) [S15].

Revenue CAGR:

  • FY2021–FY2024 (comparable June years): about +2.9% per year.

  • FY2021–FY2025 (not like-for-like, because FY2025 excludes about R1.1bn of Activo revenue): about −2.5% per year.

Balance sheet

Sources: [S1][S4][S2].

  • NAV per share for Jun-2025 and Jun-2026 is an analyst calculation: attributable equity divided by 840.7m shares.

  • Borrowings comprise a Nedbank facility (R598.9m at Jun 2026) and a Bank Windhoek mortgage loan (R27.8m) [S4].

  • Assets held for sale (Activo) were R566.0m at Dec 2025 and R592.2m at Jun 2026, including R179.5m of cash at Jun 2026 [S1][S4].

Goodwill composition:

The remaining intangible base is dominated by self-generated administration systems (R897.5m at Jun 2026) [S4].

Cash flow

Sources: [S1][S4]. Free cash flow is an analyst definition, because AfroCentric classifies dividends paid within operating activities.

Historical half-year cash generation. Cash generated from operations (excluding dividends) was R520m (Dec 2021), R270m (Dec 2022), R409m (Dec 2023), R604m (Jun 2024), R456m (Jun 2025) and R262m (Jun 2026) [S9b][S4].

Ratios (FY2025, analyst computations from [S1])

Commentary on trends, inflections and drivers.

  1. FY2021–FY2022: Covid tailwinds and acquisition-led growth.

    • Revenue rose 25.8% in FY2021 and 8% in FY2022. The drivers were the full-year inclusion of DENIS, additional GEMS managed care services, and pandemic-era pharmaceutical and vaccination demand [S40][S37].

    • Headline earnings peaked at R329m (FY2021).

    • The dividend was 34c, covered about 1.6–1.7x by HEPS.

  2. FY2023: normalisation and the change of control.

    • Pharma cluster operating profit fell 41.1% as OTC and HIV medicine sales normalised, chronic adherence dropped, and supply instability hit Activo [S16].

    • The weighted share count rose by about 39% in FY2024 after the Sanlam asset-for-share transaction (AHA minority swapped into AfroCentric equity). HEPS was therefore diluted even as minorities' share of Medscheme profits was eliminated.

  3. FY2024: impairment cycle begins.

    • R230m of impairments, including R130m on the Activo and Forrester investment of about R868m [S12]. Reported profit fell 75%.

    • Headline earnings rose 54% because of the full-year benefit of the AHA minority buy-in.

  4. Transition (6M Dec 2024) and FY2025: Bonitas erosion and a goodwill reset.

    • The loss of Bonitas DSP status (Feb 2025) cut private scripts by 33% and antiretroviral volumes by 40.5% [S6].

    • After Bonitas's 29 January 2026 award to competitors, management impaired goodwill and intangibles. The total was R1.37bn across continuing and discontinued operations, including R810.9m of continuing goodwill and R227.6m in discontinued operations [S1][S6].

    • Underlying performance was resilient: operating cash generation of R914.8m and adjusted EBITDA of about R700m.

  5. H1 2026: post-Bonitas reset begins.

    • Revenue fell 5.6% and HEPS fell 26.9% to 8.54c.

    • Continuing profit before tax still rose 25.9% to R111.4m, on cost containment and lower amortisation [S4].

    • The balance sheet moved to net cash (excluding leases) of R84m. The R300m revolving credit facility is undrawn [S4].

    • The full-year earnings impact of losing Bonitas falls in H2 2026 and FY2027. Bonitas paid roughly R1.1bn of administration fees and about R660m of managed care fees in 2024, based on CMS data [S19]. Management has not disclosed the exact revenue share.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it contains

Healthcare SA

Medscheme administration and managed care, Aid for AIDS, Klinikka, corporate solutions entities, gap and primary care insurance

DENIS Group

Dental benefit management and dental capitation

Information Technology

AfroCentric Technologies, which runs core administration platforms (the "Nexus" administration systems), decision engine and automation

Total SA administration business

The sum of the three segments above

Healthcare Africa

Medscheme Namibia, Namibia Health Risk Solutions, Medscheme Mauritius and other Southern African operations

Healthcare Retail

Pharmacy Direct, Curasana, Scriptpharm. The Activo Group was previously included and is now discontinued.

Segment revenue (ZAR Mn)

Segment revenue (ZAR Mn)H1 2025H1 2026

Healthcare SA

2,123.02,163.7

DENIS Group

301.5314.2

Information Technology

338.0346.0

Total SA administration

2,762.52,823.9

Healthcare Africa

129.6121.0

Total Group administration

2,892.12,944.9

Pharmacy Direct and Curasana

640.3484.6

Scriptpharm

702.3642.7

Healthcare Retail total

1,342.51,127.2

Inter-segment eliminations

-473.3-512.3

Group total (incl. insurance revenue)

3,761.33,559.8

Segment operating profit (ZAR Mn)

Segment operating profit (ZAR Mn)H1 2025H1 2026

Healthcare SA

99.650.8

DENIS Group

19.730.6

Information Technology

112.092.9

Total SA administration

231.4174.3

Healthcare Africa

42.747.4

Total Group administration

274.1221.7

Pharmacy Direct and Curasana

1.335.7

Scriptpharm

33.724.7

Healthcare Retail total

35.160.4

Group operating profit

309.2282.2

Segment Overview — Healthcare SA

SegmentRevenue (ZAR Mn)Operating profit (ZAR Mn)Op. margin (%)% of pre-elimination revenuePre-tax profit/(loss) (ZAR Mn)

Healthcare SA

4,292.7304.57.146.6(1,340.9)

DENIS Group

601.657.29.56.559.2

Information Technology

675.5123.618.37.3(113.8)

Total SA administration

5,569.8

485.3

8.7

60.5

(1,395.5)

Healthcare Africa

261.391.635.12.887.3

Total Group administration

5,831.1

576.9

9.9

63.3

(1,308.2)

Pharmacy Direct and Curasana

1,982.637.71.921.5105.1

Scriptpharm

1,397.264.24.615.280.9

Healthcare Retail

3,379.8

101.9

3.0

36.7

186.0

Eliminations / other

(1,764.0)———590.3

Group

7,446.8

678.8

9.1

100.0

(531.9)

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue from contracts with customers (ZAR Mn)

8,074.48,722.68,760.28,794.77,303.2

Profit before tax (ZAR Mn)

699.5675.2427.4207.0-531.9

Profit for the year incl. discontinued (ZAR Mn)

469.7481.7295.574.3-1,259.2

Basic earnings attributable (ZAR Mn)

302.0314.3183.555.4-1,274.2

Headline earnings (ZAR Mn)

329.1317.1217.3334.8117.1

Basic EPS (ZAR cents)

52.5654.5730.706.67-151.55

Headline EPS (ZAR cents)

57.2655.0736.3440.3213.92

Diluted EPS (ZAR cents)

52.5654.5730.706.67-149.41

Dividends per share (ZAR cents)

34340110

Weighted average shares (millions)

574.7575.9597.8830.3840.75

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Pre-tax margin (%)

8.77.74.92.4-7.3

Net margin incl. discontinued (%)

5.85.53.40.8-17.2

Headline earnings margin (%)

4.13.62.53.81.6

Step Details

StepR m

Reported loss before tax (continuing)

-531.9

Add finance costs plus lease interest

+75.5

Less finance income

-55.0

Add depreciation, right-of-use depreciation and amortisation (124.0 + 60.1 + 202.1)

+386.2

Reported EBITDA

-125.4

Add back impairments (goodwill 810.9, intangibles 11.2, PPE 1.3, right-of-use 1.5)

+824.9

Adjusted EBITDA

≈699.5

Balance Sheet and Per-Share Data

Metric (ZAR Mn)Dec-2024Jun-2025Dec-2025Jun-2026

Total assets

5,162.55,449.44,180.53,986.8

Cash and cash equivalents (excl. held for sale)

347.8483.2607.4710.9

Borrowings – current

62.472.253.149.8

Borrowings – non-current

556.7582.1574.1576.9

Total borrowings

619.1654.2627.2626.7

Lease liabilities

171.7144.3116.4130.5

Net debt excl. leases

271.3171.119.9-84.2

Net debt incl. leases

443.0315.4136.346.3

Total equity

3,279.13,329.81,943.02,016.9

Equity attributable to owners

3,245.73,289.91,902.81,975.6

Goodwill and intangible assets

2,541.42,501.31,047.61,004.2

Working capital (current assets less current liabilities, excl. held for sale)

559.6610.7263.4321.5

NAV per share (ZAR cents)

390391231235

Returns & Leverage Ratios

Goodwill (ZAR Mn)Jun-2025Jun-2026

AfroCentric Health

705.330.0

Pharmacy Direct and Curasana

140.65.0

DENIS

34.934.9

Activo and Activo Healthcare Assets

227.6

nil (held for sale)

Total

1,108.5

69.9

Cash Flow

Metric (ZAR Mn)6M-Dec-2024FY2025H1-2026

Cash generated from operations

343.2914.8262.2

Net cash from operating activities

249.3684.9218.2

Capex – property and equipment

64.596.525.3

Capex – intangible assets

70.5122.98.9

Total capex

135.0219.334.2

Dividends paid (incl. to non-controlling interests)

4.658.53.9

Share buybacks

1.10.00.0

Free cash flow (net operating CF + dividends paid − capex)

118.9524.1187.9

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025Basis

ROE (attributable loss / average attributable equity)

-49.5%

Loss of R1,274.2m ÷ average equity of R2,574.3m

Headline ROE

4.5%

Headline earnings of R117.1m ÷ R2,574.3m

ROA (loss / average total assets)

-27.0%

Loss of R1,259.2m ÷ R4,671.5m

ROIC (adjusted)

≈11%

Adjusted EBIT R313.3m × (1 − 27%) ÷ year-end invested capital ≈ R2,079m

Current ratio (excl. held for sale)

1.21x

Dec 2024: 1.58x

Current ratio (incl. held for sale)

1.54x—

Debt / equity (borrowings only)

0.32x

Dec 2024: 0.19x

Net debt / adjusted EBITDA (incl. leases)

0.19x

R136.3m ÷ R699.5m

Interest coverage (adjusted EBIT / finance costs incl. leases)

≈4.1x

R313.3m ÷ R75.5m

Asset turnover

1.56x

Revenue ÷ average total assets

Receivable days

≈26 days

R521.1m ÷ R7,303.2m × 365

Inventory days (on product cost of sales)

≈45 days

R107.3m ÷ R861.4m × 365

Cash conversion cycle

Not meaningful / not disclosed

The predominantly service business and the held-for-sale reclassification distort payables metrics

Revenue by geography (ZAR Mn)

Revenue by geography (ZAR Mn)H1-2025FY2025H1-2026

South Africa

3,564.17,041.93,364.5

Outside South Africa (Healthcare Africa)

129.6261.3121.0

Group revenue from contracts with customers

3,693.67,303.23,485.4

Segment Overview (2)

SegmentSouth AfricaOutside SATotal

Healthcare SA

2,403.5—2,403.5

Healthcare Africa

—121.0121.0

Healthcare Retail

1,127.2—1,127.2

Information Technology

346.0—346.0

Intercompany eliminations

(512.3)—(512.3)

Group

3,364.5

121.0

3,485.4

Share price metric (ZAR cents)

Share price metric (ZAR cents)Jun-2021Jun-2022Jun-2023Jun-2024Dec-2024Oct-2026

Period-end share price (ZAR cents)

44243941528819966

Market Valuation

Market capitalisation (ZAR Mn)Dec-2023Dec-2024Jul-2025Oct-2026

Market capitalisation (ZAR Mn)

2,732.71,673.81,420.0555.1

Start Point by Horizon

HorizonStart pointChange

≈5-year

Jun 2021 (442c)

−85%

≈3-year

Jun 2023 (415c)

−84%

≈15-month

Jul 2025 (169c)

−61%

Valuation Snapshot

MultipleValueBasis

Price / headline earnings (FY2025)

4.7x

HEPS 13.92c

Price / headline earnings (trailing 12m to Jun 2026)

6.1x

HEPS ≈10.78c (13.92 − 11.68 + 8.54)

P/B

0.28x

NAV ≈235c at Jun 2026

EV

≈R643m

Market cap 555.1 + borrowings 626.7 + leases 130.5 + non-controlling interests 41.3 − cash 710.9

EV / Sales (FY2025)

0.09x—

EV / adjusted EBITDA (FY2025)

0.92x

≈R699.5m. Forward EBITDA will be materially lower after Bonitas, so this multiple overstates cheapness.

Ex-date Details

Ex-dateAmount (ZAR cents)Period

11 Nov 2020

17

Final FY2020

12 May 2021

17

Interim FY2021

10 Nov 2021

17

Final FY2021

11 May 2022

17

Interim FY2022

9 Nov 2022

17

Final FY2022

8 May 2024

11

Interim (6M Dec 2023)

7 May 2025

6

6M Dec 2024

—

nil

FY2025 (capital preservation)

Analyst Conclusions

Management guidance. There is no quantitative guidance. The Board expects a "challenging" environment while it completes the Bonitas wind-down, organisational redesign, cost reset and portfolio simplification. It explicitly flags that the full financial impact of the contract loss will appear in future periods [S4].

Consensus. Not publicly available.

Bull case

  1. The cost reset can protect earnings faster than revenue falls.

    • H1 2026 continuing PBT rose 25.9% on a 5.6% revenue decline [S4].

    • The Bonitas fee pool (≈R1.76bn per year by CMS-based estimates) carried substantial dedicated cost, now being removed through Section 189A [S19][S4].

  2. The balance sheet and valuation offer a margin of safety.

    • Net cash excluding leases, plus an undrawn R300m revolving credit facility.

    • Shares at about 0.28x book and below 1x trailing adjusted EBITDA on EV.

    • Activo deferred consideration (≈R196m) still to flow in [S4].

  3. A higher-quality earnings mix. The specialist capitation businesses (DENIS, oncology, spinal) and Healthcare Africa (35% margin) are growing. The integrated Sanlam proposition could win restricted-scheme and employer mandates, as Sisonke shows [S4][S6].

Bear case

  1. The revenue cliff is not yet in the numbers. Only one month of Bonitas loss falls in H1 2026. Healthcare SA operating profit already halved to R50.8m [S4].

  2. Contract churn may continue. Management cites tighter procurement cycles and several renewals in 2025 [S7]. The Bonitas dispute may weigh on reputation with trustees, while Discovery and the enlarged Momentum gain scale [S33].

  3. Minority shareholders are structurally disadvantaged.

    • Sanlam controls 58.81% and carries the stake at nil in its own books [S24].

    • Related-party disposals were done at NAV (ADS) [S4].

    • Dividends are suspended and liquidity is thin.

    • The R897.5m software intangible base remains subject to impairment testing [S1][S4].

Key catalysts and monitorables (next 12 months)

  1. FY2026 trading statement and results (expected around Feb–Mar 2027). Watch the full H2 impact of Bonitas, restructuring savings and any further software or goodwill impairments.

  2. New business wins or losses at upcoming scheme tenders, and retention of GEMS, POLMED and Fedhealth.

  3. Outcome of the CMS Section 44 investigation into Bonitas and any regulatory findings.

  4. Activo deferred consideration and earnout settlement, and use of proceeds.

  5. Sanlam's intentions. Possible capital support, a minority buy-out or further asset transfers (none announced).

  6. Dividend reinstatement policy and capital allocation under the "sequencing" framework.

  7. Pharmacy Direct CCMDD contract terms and pricing, and NHI legislative progress.

  8. Headcount and cost disclosures that quantify the reset.

Analyst verdict

AfroCentric enters late 2026 as a fundamentally changed business. For most of the past decade the equity story was a healthcare ecosystem built around Medscheme's scale and Bonitas's anchor contract, with pharmaceutical integration and Sanlam distribution as accelerants. That story has broken in three steps:

  • The pharmaceutical integration failed. Activo was bought out at R588m, impaired twice and sold for an expected value of about R285m.

  • The Bonitas relationship ended after 43–44 years, taking with it roughly 680,000–750,000 beneficiaries and an estimated R1.7bn-plus of annual fees.

  • A R1.37bn impairment reset cut NAV per share from 390c to 231c in a single year.

What remains is smaller but more coherent and, on the evidence, cash-generative:

  • A retained base of about 3.3m lives.

  • A highly automated administration platform.

  • Profitable specialist capitation lines.

  • A Southern African business earning 35% margins.

  • A public-sector courier pharmacy with record volumes.

The balance sheet is ungeared on a net basis, liquidity is ample, and the parent is publicly committed.

The investment question is whether the cost base can be cut to match the post-Bonitas revenue line before further contract attrition occurs. H1 2026 is encouraging on cost discipline: continuing PBT rose despite falling revenue. But H1 2026 contains only one month of the Bonitas loss, so FY2026 and H1 2027 are the real tests.

At about R555m market capitalisation, 0.28x book and about 6x trailing headline earnings, the market is pricing in sustained decline. That pricing looks overly punitive if management stabilises the scheme book and delivers the cost reset. It looks fair if a second large client defects.

The minority shareholder's position is constrained. Sanlam controls the outcome, liquidity is thin, dividends are suspended, and any value-crystallising event (a buy-out or restructuring) is at the parent's discretion.

Verdict: a high-risk, deep-value special situation. Visibility is lowest until the FY2026 results confirm the post-Bonitas earnings run-rate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationTotal compensation

Gerald (GN) van Wyk

Group CEO, executive director

Joined 1 Aug 2023; CEO from 1 Nov 2023

CEO Client Solutions, Santam; Executive Head Strategic Business Development, Santam; roles at Discovery Insure, Mutual & Federal and Hollard; former chair of Indwe Broker Holdings; past president of the Insurance Institute of Gauteng

BCom Risk Management (Unisa); MDP (Stellenbosch); GMP (Harvard)

—

Thato (KT) Moloele

Group CFO, executive director

CFO-designate 1 Jan 2025; CFO from 1 Feb 2025

—

CA(SA)

—

Andrew (AD) Schwulst

CEO, Medscheme (subsidiary)

From 2023

Former CEO, Liberty Health

—

R5.717m (FY2025, total cost to company plus incentives)

Lebohang Mpumlwana

Group Company Secretary

————

Bongiwe Ncube

General Manager: Group Finance

——

CA(SA)

—

“—” = not publicly disclosed.

Executive Leadership Team by Executive

ExecutiveTotal cost to company and incentives

D Carolus

6,236 (includes a 36-month retention bonus with clawback)

AD Schwulst

5,717

AA Mahmood

5,073

FV Nompumza

5,062

MS Bray

4,303

Board of Directors

DirectorRoleAppointedFY2025 fees (ZAR K)Notes

Prof Anna (ATM) Mokgokong

Chairman, non-executive

10 Jun 2010

2,039

Indirect holding of 3.96%

José Bruno Fernandes

Lead Independent NED; Chair of Audit and Risk Committee

23 Nov 2018

1,438

CA(SA)

Alice Marie le Roux

Independent NED; Audit and Risk Committee member

25 May 2020

896

CA(SA) & RA

Karabo Morule

Independent NED; Audit and Risk Committee member

31 Dec 2024

738

Actuary (FIA, FASSA)

CK Mokoena

Independent NED

1 Oct 2025

150—

MJ Madungandaba

Non-executive (former Deputy Chairman)

10 Jun 2010

978

Indirect holding of 4.94%

Dr Nkateko (ND) Munisi

Non-executive; moved to Remuneration Committee on 24 Feb 2026

7 Dec 2015

657

Holding of 4.41%

Paul (PB) Hanratty

Non-executive (Sanlam Group CEO)

12 Jun 2023

nil

Sanlam executives are not remunerated

KN Mkhize

Non-executive (Sanlam)

20 Jun 2022

nil

—

Zakhe Zuma

Director; Investment Committee member

17 Sep 2026

—

ARC principal transactor.

Gerald van Wyk

Executive (CEO)

1 Aug 2023

——

Thato Moloele

Executive (CFO)

1 Jan 2025

——

Major Shareholders

HolderShares%

Sanlam Life Insurance Limited (strategic)

494,431,62958.81

Community Healthcare Holdings (Pty) Ltd (director-associated)

74,098,6728.81

ARC Financial Services Investments (Pty) Ltd

62,912,4837.48

Visio Capital Management

47,730,2205.68

Definitive Capital Management

2,702,5250.32

Pershing Securities Limited

1,608,1140.19

Bank Julius Baer & Co

665,0190.08

Peresec Prime Brokers

573,1960.07

Nedbank Private Wealth

349,9120.04

Barnard Jacobs Mellet

244,6410.03

Investec Private Clients

131,8270.02

Melville Douglas Investment Management

120,0000.01

Competitive Landscape

Market Share by Competitor

CompetitorSegment(s)Relative positioning vs AfroCentricRevenue / share data (verified)

Discovery Health (Discovery Ltd)

Scheme administration, managed care

Dominant open-scheme administrator; highest admin fee (R387.08 pampm, 2024)

DHMS 33.1% of principal members (2024).

Momentum Health Solutions (Momentum Group)

Administration, managed care

Now administers Bonitas; ≈30% administration market share post-win

Momentum targets FY2027 normalised headline earnings of R7bn (group)

Private Health Administrators (PHA)

Managed care

Won the Bonitas managed care mandate; named in procurement allegations

—

Agile Business Solutions

Scheme marketing and distribution

Won the Bonitas marketing tender from ADS (2024)

—

Medihelp (self-administered scheme)

Administration (in-house)

Former POLMED administrator

—

Bestmed (self-administered scheme)

Administration (in-house)

Lowest managed care cost among large schemes (R116.11 pmpm)

—

3Sixty Health

Administration

Mid-tier administrator

—

Universal Healthcare

Administration and managed care

Mid-tier administrator

—

Lifesense / other HIV management providers

Disease management (vs AfA)

Specialist competitor

—

Dental benefit managers (e.g., Dental Risk Company)

Dental capitation (vs DENIS)

Specialist competitor

—

Courier and chronic medicine distributors (e.g., Medipost; retail pharmacy chains Clicks and Dis-Chem)

Courier pharmacy, CCMDD (vs Pharmacy Direct)

Pharmacy Direct is self-described as the country's largest courier pharmacy

—

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricAfroCentric (FY2025)Sanlam (parent, context)

Revenue

R7.3bn (continuing)

—

Revenue growth

Not comparable (year-end change). H1 2026: −5.6%.

—

Operating margin

9.1% (non-IFRS)

—

R&D / tech intensity

≈1.6% capitalised software; ≈5.5% including IT opex

—

Market cap

≈R0.56bn (Oct 2026)

≈R175bn (Sep 2026)

Company Snapshot

5,899

Employees

1988

Founded

Roodepoort, South Africa

Headquarters

SWOT Analysis

Strengths

  • Cash generation despite accounting losses. Cash generated from operations was R914.8m in FY2025 against a basic loss of R1,274m [S1].
  • Balance sheet now net cash. Net cash excluding leases was R84.2m at Jun 2026, with a R300m undrawn revolving credit facility [S4].
  • High-margin specialist units. Healthcare Africa: 35% operating margin in FY2025 [S4]. DENIS: operational earnings +26.2% [S6]. Scriptpharm oncology: profitability +29% [S6].
  • Scale and automation of the claims platform. About 10.2m claim lines per month, more than 99% auto-processed. Hospital claim automation at 76%, up 28% on legacy [S7].
  • Public-sector distribution scale. CCMDD volumes of 1.417m scripts per month (+6.6%) serving 2.4m+ patients [S6].
  • Controlling shareholder support. Sanlam owns 58.81%, ruled out a sale, and supports the turnaround [S1][S24].
  • Retained client base. About 3.3m beneficiaries, including GEMS (managed care), POLMED and Fedhealth, plus a new Sisonke win [S17][S18][S4].

Weaknesses

  • Client concentration exposed. Bonitas (≈680k beneficiaries; ≈R1.76bn per year of admin and managed care fees per CMS-based estimates) was lost after 43–44 years [S20][S19].
  • Serial impairments signal past capital misallocation. R230m in FY2024 [S12]. R1.37bn in FY2025 [S6]. Activo bought out at R588m and ultimately sold for an expected value of about R285m [S28b][S4].
  • Thin retail margins. Pharmacy Direct and Curasana earned a 1.9% operating margin in FY2025 [S4]. The courier trading margin fell from 6.8% to 2.2% [S6].
  • Earnings decline. HEPS fell from 57.26c (FY2021) to 13.92c (FY2025) and 8.54c (H1 2026) [S13][S2][S4].
  • Compliance lapses disclosed in the FY2025 Directors' Report [S1]:
  • late CIPC filings
  • late FSCA filing for Essential Medical
  • outstanding SARS returns at Activo Healthcare Assets
  • a Pharmacy Act s22A ownership contravention
  • Limited free float and liquidity. Public shareholders hold 25.12%, and Sanlam plus related parties control about 75% [S1].

Opportunities

  • Value-based care. Scaling the spinal risk transfer model, which reached break-even in its pilot, to other conditions [S6].
  • Sanlam ecosystem cross-sell. Gap cover, primary care, Health Rewards and corporate wellness through Sanlam distribution [S1][S7].
  • New mandates as procurement cycles turn. Sisonke demonstrates competitive tender wins [S4].
  • NHI-aligned public delivery. Pharmacy Direct is positioned as a key government partner [S4].
  • Operating leverage from the cost reset. H1 2026 continuing PBT rose 25.9% on lower costs even as revenue fell [S4].
  • Activo deferred consideration. About R196m of working-capital payments plus a capped earnout of R90m are still to be received [S4].

Threats

  • Further contract churn. Several key contracts approached renewal during 2025 [S7]. Momentum and Discovery are consolidating scale [S33].
  • Reputational damage from the Bonitas dispute and transition. Public blame exchanges in June 2026 [S23].
  • Regulatory outcomes. The CMS Section 44 investigation outcome is uncertain. The broadened scope is disputed [S41].
  • Public-sector price compression. A net decline in price per script on CCMDD [S4].
  • Market contraction. Medical scheme coverage is shrinking relative to the population, with an ageing membership [S33].
  • Execution risk on the cost reset. The Sanlam CEO acknowledged "execution challenges ahead" [S24].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Pharma cluster cost rationalisation programme implemented [S6]Restored Pharmacy Direct and Curasana profitability by H1 2026
Apr 2025Data centre relocation completed; AfroCentric Technologies adopts a new platform [S7], [S9b]IT resilience
12 May 2025AGM; all resolutions passed. 6c dividend paid (6M Dec 2024). [S32], [S31]Last dividend to date
H1 2025Silberstein Trading Enterprises acquired (R75.6m); Demushuwa sold (R35.8m) [S4]Portfolio adjustments
1 Jul 2025Medgap (Guardrisk) cell ceases underwriting [S4]Simplification of insurance participation
24 Jul 2025ADS Group and Wellworx sale to Sanlam Life completed [S6], [S4]Distribution moved into Sanlam
1 Sep 2025Trading statement for H1 2025: HEPS expected at 11.30–12.06c [S10]Earnings guidance
2 Sep 2025H1 2025 results: revenue −2.6% to R4,211m; HEPS 11.68c (−38.5%) [S9]Retail pressure from Bonitas DSP loss
1 Oct 2025CK Mokoena appointed Independent NED [S1]Board refresh
21 Oct 2025Business Day column publishes whistle-blower allegations on Bonitas procurement [S19]Catalyst for regulatory action
Nov 2025CMS concludes its Section 43 inquiry into Bonitas; Section 44 forensic investigation instituted [S19], [S41]Regulatory backdrop to the contract dispute
15 Dec 2025Medscheme files an urgent High Court application to suspend the Bonitas RFP awards pending the CMS probe [S17]Litigation risk
23–24 Dec 2025Activo SPA with FHC Group (R350m upfront plus earnout up to R250m) [S25]Exit from manufacturing
29 Jan 2026Bonitas awards administration to Momentum Health and managed care to PHA from 1 Jun 2026; SENS alert [S18], [S4]Loss of largest client (≈680–750k beneficiaries)
2 Feb 2026Bonitas argues the interdict is moot and alleges Medscheme was loss-making for the scheme [S21]Dispute escalates
19 Feb 2026Medscheme answering affidavit; Daily Maverick estimates Bonitas admin and managed care fees at ≈R1.76bn per year [S19]Quantifies exposure
20 Feb 2026JSE extends the Activo Category 1 circular deadline to 24 Apr 2026 [S27]Deal timing
1 Mar 2026Medscheme marks 55 years [S4]Brand milestone
2 Mar 2026FY2025 trading statement: loss per share 150–153c; HEPS 13.5–14.25c [S3]Impairment pre-announcement
3–4 Mar 2026Bonitas urgent application removed from the roll [S20]Litigation stalls
4 Mar 2026FY2025 results: revenue R7,303m (continuing); basic loss R1,274m; HEPS 13.92c; NAV 231c; no dividend [S2]Balance sheet reset
6 Mar 2026Marinda Dippenaar resigns as NED [S4]Board change
23 Apr 2026Revised Activo SPA: upfront cut to R100m; earnout cap R90m [S4], [S27]Value erosion linked to Bonitas
1 May 2026Medscheme begins administering Sisonke Health Medical Scheme (mining sector) [S4], [S22]New business win
31 May 2026Bonitas contracts end; wind-down periods begin (4 months administration, 2 months managed care) [S17]Revenue step-down
Early Jun 2026Public dispute over Bonitas member service backlogs after the switch [S23]Reputational exposure for all parties
H1 2026Section 189A retrenchment process for Bonitas-servicing staff [S4]Cost reset
16 Jul 2026Medscheme withdraws its High Court application, relying on the CMS investigation [S4]Litigation closed
Jul 2026Share price trades down to about R0.70 [S31]Market cap below R600m
31 Jul 2026Activo suspensive conditions fulfilled [S4]Deal unconditional
24 Aug 2026Court dismisses Neil Harvey & Associates' review application against Medscheme, with costs awarded to Medscheme [S4]Favourable legal outcome
31 Aug 2026Activo disposal implemented [S4]Simplification completed
1 Sep 2026H1 2026 results: revenue −5.6% to R3,485m; HEPS 8.54c (−26.9%); continuing PBT +25.9% [S4]First post-Bonitas print
8 Sep 2026FHC outlines a sterile-injectables plan for Activo [S26]Buyer strategy; earnout relevance
17 Sep 2026Zakhe Zuma (ARC) appointed to the board and Investment Committee [S24]Board strengthened for the transaction agenda
18 Sep 2026Sanlam CEO: stake written down to nil in Sanlam's books; no intention to sell; "rightsizing exercise" under way [S24]Parent support affirmed
13 Oct 2026Share price R0.66; market cap ≈R555m [S31]Valuation trough

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Totals: Total SA administration rose from ZAR 2,762.5 Mn in H1 2025 to ZAR 2,823.9 Mn in H1 2026.
AfroCentric Investment Corporation Limited — Revenue by Segment: Totals
Series (ZAR Mn)H1 2025H1 2026
Total SA administration2,762.52,823.9
Total Group administration2,892.12,944.9
Group total (incl. insurance revenue)3,761.33,559.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1AfroCentric Consolidated and Separate Annual Financial Statements, year ended 31 Dec 2025 (KPMG audited) — 3 Mar 2026 (senspdf.jse.co.za)
  2. S2SENS: Summarised results for the year ended 31 Dec 2025 — 4 Mar 2026 (sharedata.co.za)
  3. S3SENS: Trading statement for the year ended 31 Dec 2025 — 2 Mar 2026 (sharedata.co.za)
  4. S4Unaudited Interim Results Booklet, six months ended 30 Jun 2026 — 1 Sep 2026 (afrocentric.za.com)
  5. S5H1 2026 results commentary (web) — 1 Sep 2026 (afrocentric.za.com)
  6. S6Integrated Annual Report (online) – CFO's review, FY2025 — 2026 (afrocentric.za.com)
  7. S7Integrated Annual Report (online) – Results at a glance / cluster performance, FY2025 — 2026 (afrocentric.za.com)
  8. S7bTracenable waste-management disclosure review — 2025 (tracenable.com)
  9. S8Integrated Annual Report (online) – landing page — 2026 (afrocentric.za.com)
  10. S9SENS: Unaudited interim results H1 2025; FilingReader summary — 2 Sep 2025 · filingreader.com
  11. S9bInterim results booklet H1 2025 — 2 Sep 2025 (senspdf.jse.co.za)
  12. S10SENS: Trading statement H1 2025 — 1 Sep 2025 (sharedata.co.za)
  13. S11SENS: Summarised results, six months ended 31 Dec 2024 — 3 Mar 2025 (sharedata.co.za)
  14. S11bSummarised results booklet, 6M Dec 2024; AFS 6M Dec 2024 — Mar 2025 · senspdf.jse.co.za
  15. S11cSENS: Trading statement (6M Dec 2024) — 27 Feb 2025 (sharedata.co.za)
  16. S12SENS: Summarised annual results FY2024; FY2024 commentary — 3 Sep 2024 · afrocentric.za.com
  17. S12bFY2024 results presentation — 4 Sep 2024 (afrocentric.za.com)
  18. S13SENS: Summarised audited results FY2022 — 13 Sep 2022 (senspdf.jse.co.za)
  19. S13bFY2022 summary of annual results — Sep 2022 (senspdf.jse.co.za)
  20. S14SENS: Interim results, six months ended 31 Dec 2023 — 4 Mar 2024 (senspdf.jse.co.za)
  21. S15SENS: Summarised audited results FY2020 — 14 Sep 2020 (senspdf.jse.co.za)
  22. S15bSENS: Interim results Dec 2016 — 28 Mar 2017 (sharedata.co.za)
  23. S16Business Day: "AfroCentric skips dividend as annual profit plunges" — 18 Sep 2023 (businessday.co.za)
  24. S17AfroCentric: Transfer of Bonitas administration statement — Jun 2026 (afrocentric.za.com)
  25. S18Business Day: "Bonitas severs ties with administrator Medscheme" — 30 Jan 2026 (businessday.co.za)
  26. S19Daily Maverick: "The numbers behind the Medscheme/Bonitas bombshell litigation" — 19 Feb 2026 (dailymaverick.co.za)
  27. S20Business Day: "Medscheme's tenders case against Bonitas removed from roll" — 4 Mar 2026 (businessday.co.za)
  28. S21Business Day: "Bonitas pushes back against Medscheme court bid" — 2 Feb 2026 (businessday.co.za)
  29. S22Moonstone: "Medscheme secures Sisonke administration mandate"; "Bonitas transition proceeds…" — 2026 · moonstone.co.za
  30. S23TimesLIVE / The Herald: "Bonitas blames Medscheme for medical scheme backlog" — 5 Jun 2026 (timeslive.co.za)
  31. S24Business Day: "Sanlam sees value in AfroCentric stake despite Bonitas blow" — 18 Sep 2026 (businessday.co.za)
  32. S25FilingReader: "AfroCentric to sell Activo Health for up to R600m"; Business Day (24 Dec 2025); SENS detailed terms — 24 Dec 2025 · businessday.co.za · sharedata.co.za
  33. S25bGhost Bites: AfroCentric sells Activo (liquidity comment) — 2026 (ghostmail.co.za)
  34. S26Business Day: "Portuguese pharmaceutical group FHC moves into sterile injectables" — 8 Sep 2026 (businessday.co.za)
  35. S27SENS: Update on Activo disposal circular — 20 Feb 2026 (sharedata.co.za)
  36. S27bSENS: Revised Activo SPA announcement — 23 Apr 2026 (sharedata.co.za)
  37. S28Moonstone / BusinessTech / Ghost Bites / Daily Investor: Sanlam offer coverage — Oct 2022 · ghostmail.co.za
  38. S28bTradingView analyst note (Activo 74% buyout at R588m) — 2023–2025 (tw.tradingview.com)
  39. S28cInvestec / Capitalmind deal notes; SENS finalisation of the partial offer — 2023 · senspdf.jse.co.za
  40. S29Business Day / News24: AfroCentric appoints Gerald van Wyk as CEO; Schwulst as Medscheme CEO — 3 Jul 2023 · news24.com
  41. S30MarketScreener insider profile: Gerald van Wyk (marketscreener.com)
  42. S31Mansa Markets: ACT share price, market cap, dividend history — 13 Oct 2026 (mansamarkets.com)
  43. S31bSimply Wall St: company profile (countries of operation) — 2026 (simplywall.st)
  44. S32ShareData Online: ACT main page (market cap, results summary) — 2025 (sharedata.co.za)
  45. S32bProfile's Stock Exchange Handbook 2025, Issues 3 and 4 — 2025 · sharedata.co.za
  46. S32cShareData Online summary quote (4 Jul 2025) — Jul 2025 (sharedata.co.za)
  47. S33Moonstone: "7 facts reshaping medical schemes"; IOL (CMS 2024 report); Briefly/BusinessTech (Momentum market share) — 2025–2026 · iol.co.za · briefly.co.za
  48. S34FA News: "Medscheme awarded POLMED administration and managed care contracts" — Sep 2015 (fanews.co.za)
  49. S34bSAPS joint media statement: Polmed tender awarded to Medscheme — Jul 1997 (polity.org.za)
  50. S34cNews24: "Medscheme wins Fedsure contract" — May 2001 (news24.com)
  51. S34dFA News: Lethimvula interim results (CMS admin fee benchmark) — historical (fanews.co.za)
  52. S35SustainabilityReports.com: AfroCentric 2023 Integrated Report summary — 2023 (sustainabilityreports.com)
  53. S36Tracenable: AfroCentric board composition data — 2025 (tracenable.com)
  54. S37AfroCentric press release: FY2022 annual results — Sep 2022 (afrocentric.za.com)
  55. S38Daily Maverick: "Sanlam flexes chequebook…" (GEMS/Activo CMS probe reference) — 2022 (dailymaverick.co.za)
  56. S39Profile's Stock Exchange Handbook 2025, Issue 2 (employees 5,899; founded/listed 1988) — 2025 (sharedata.co.za)
  57. S40FY2021 summary of annual results (DENIS acquisition; revenue +25.8%) — Sep 2021 (senspdf.jse.co.za)
  58. S41Moonstone tag page: Bonitas/Medscheme CMS investigation scope dispute — Jul 2026 (moonstone.co.za)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.